MCID: GLL017
MIFTS: 42

Gallbladder Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gallbladder Adenocarcinoma

MalaCards integrated aliases for Gallbladder Adenocarcinoma:

Name: Gallbladder Adenocarcinoma 12 15 17 70
Adenocarcinoma of the Gallbladder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3500
NCIt 50 C9166
UMLS 70 C0279651

Summaries for Gallbladder Adenocarcinoma

Disease Ontology : 12 A gallbladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gallbladder Adenocarcinoma, also known as adenocarcinoma of the gallbladder, is related to gallbladder cancer and large cell neuroendocrine carcinoma, and has symptoms including abdominal pain An important gene associated with Gallbladder Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are MicroRNAs in cancer and mTOR signaling pathway (KEGG). The drugs Oxaliplatin and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Gallbladder Adenocarcinoma

Diseases related to Gallbladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 234)
# Related Disease Score Top Affiliating Genes
1 gallbladder cancer 31.3 TP53 PIK3CA ERBB2 EGFR
2 large cell neuroendocrine carcinoma 30.7 KRT20 ERBB2 EGFR
3 adenocarcinoma 30.6 TP53 PIK3CA KRT20 ERBB2 EPHA7 EGFR
4 in situ carcinoma 30.4 TP53 PIK3CA ERBB2 EGFR
5 clear cell adenocarcinoma 30.2 TP53 PIK3CA KRT20
6 gallbladder disease 30.2 TP53 ERBB2 EGFR
7 carcinosarcoma 30.2 TP53 PIK3CA ERBB2 EGFR
8 adenosquamous carcinoma 30.1 TP53 PIK3CA EGFR
9 mucinous adenocarcinoma 30.1 TP53 KRT20 ERBB2 EGFR
10 signet ring cell adenocarcinoma 30.1 TP53 KRT20 ERBB2
11 tubular adenocarcinoma 30.0 KRT20 ERBB2 EGFR
12 malignant astrocytoma 29.9 TP53 PROM1 ERBB2 EGFR
13 cholangiocarcinoma 29.9 TP53 PIK3CA KRT20 ERBB2 EGFR
14 small cell carcinoma 29.9 TP53 KRT20 ERBB2 EGFR
15 pancreatic ductal adenocarcinoma 29.9 TP53 PROM1 ERBB2 EGFR
16 papilloma 29.9 TP53 KRT20 ERBB2 EGFR
17 gastric adenocarcinoma 29.9 TP53 PIK3CA KRT20 ERBB2
18 intrahepatic cholangiocarcinoma 29.7 TP53 PROM1 KRT20 ERBB2 EGFR
19 bile duct cancer 29.7 TP53 PROM1 KRT20 ERBB2 EGFR
20 bladder cancer 29.5 TP53 PSCA PIK3CA KRT20 ERBB2 EGFR
21 leukemia, chronic lymphocytic 29.2 TP53 PEG10 MYB ERBB2 EGFR
22 adenocarcinoma of the gallbladder and extrahepatic biliary tract 11.4
23 gallbladder pleomorphic giant cell adenocarcinoma 11.3
24 hepatoid adenocarcinoma 10.5
25 cholecystitis 10.4
26 gastric papillary adenocarcinoma 10.4 TP53 ERBB2
27 apocrine adenosis of breast 10.4 TP53 ERBB2
28 esophagus verrucous carcinoma 10.4 TP53 EGFR
29 breast scirrhous carcinoma 10.4 ERBB2 EGFR
30 esophageal basaloid squamous cell carcinoma 10.4 TP53 EGFR
31 parotid gland cancer 10.4 TP53 ERBB2
32 breast juvenile papillomatosis 10.4 PIK3CA ERBB2
33 frontal lobe neoplasm 10.4 TP53 EGFR
34 comedo carcinoma 10.4 TP53 ERBB2
35 penile benign neoplasm 10.4 TP53 PIK3CA
36 breast metaplastic carcinoma 10.4 ERBB2 EGFR
37 adenosquamous lung carcinoma 10.4 PIK3CA EGFR
38 submandibular gland cancer 10.4 ERBB2 EGFR
39 spinal cord oligodendroglioma 10.4 TP53 EGFR
40 breast sarcoma 10.4 TP53 ERBB2
41 pleomorphic adenoma carcinoma 10.4 TP53 ERBB2
42 soft tissue sarcoma 10.4 TP53 EGFR
43 parameningeal embryonal rhabdomyosarcoma 10.3 TP53 PIK3CA
44 supraglottis cancer 10.3 TP53 EGFR
45 mammary analogue secretory carcinoma 10.3 TP53 EGFR
46 esophageal adenosquamous carcinoma 10.3 TP53 ERBB2
47 localized osteosarcoma 10.3 TP53 ERBB2
48 cystadenocarcinoma 10.3 TP53 PIK3CA ERBB2
49 ovarian carcinosarcoma 10.3 TP53 PIK3CA ERBB2
50 progesterone-receptor negative breast cancer 10.3 ERBB2 EGFR

Graphical network of the top 20 diseases related to Gallbladder Adenocarcinoma:



Diseases related to Gallbladder Adenocarcinoma

Symptoms & Phenotypes for Gallbladder Adenocarcinoma

UMLS symptoms related to Gallbladder Adenocarcinoma:


abdominal pain

GenomeRNAi Phenotypes related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.5 PIK3CA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-118 9.5 EGFR
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-130 9.5 ERP29
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 9.5 PIK3CA
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 9.5 PIK3CA
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 9.5 PIK3CA
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 9.5 PIK3CA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 9.5 EGFR PIK3CA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-197 9.5 ERP29
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.5 PIK3CA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 9.5 PIK3CA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.5 PIK3CA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.5 PIK3CA
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.5 EGFR

MGI Mouse Phenotypes related to Gallbladder Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.03 CD82 EGFR ERBB2 ERP29 MSI1 MTDH
2 cardiovascular system MP:0005385 10.02 CD82 EGFR ERBB2 MCAM MSI1 MTDH
3 neoplasm MP:0002006 9.81 CD82 EGFR ERBB2 MTDH PIK3CA PROM1
4 no phenotypic analysis MP:0003012 9.5 EGFR MCAM MYB PIK3CA PROM1 SLC29A1
5 normal MP:0002873 9.28 EGFR ERBB2 MSI1 MTDH MYB PROM1

Drugs & Therapeutics for Gallbladder Adenocarcinoma

Drugs for Gallbladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
2
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
3
Gemcitabine Approved Phase 3 95058-81-4 60750
4 Antimetabolites Phase 3
5 Liver Extracts Phase 3
6 Anti-Infective Agents Phase 3
7 Immunosuppressive Agents Phase 3
8 Immunologic Factors Phase 3
9 Antiviral Agents Phase 3
10
Bevacizumab Approved, Investigational Phase 2 216974-75-3
11
Melphalan Approved Phase 2 148-82-3 4053 460612
12
Pancrelipase Approved, Investigational Phase 2 53608-75-6
13
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
14 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
15
Molgramostim Investigational Phase 2 99283-10-0
16 Angiogenesis Inhibitors Phase 2
17 Alkylating Agents Phase 2
18 pancreatin Phase 2
19 Cola Phase 2
20 Freund's Adjuvant Phase 2
21 Adjuvants, Immunologic Phase 2
22 Vaccines Phase 2
23
Metronidazole Approved Phase 1 443-48-1 4173
24
Durvalumab Approved, Investigational Phase 1 1428935-60-7
25
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
26
Atezolizumab Approved, Investigational Phase 1 1380723-44-3
27
Guadecitabine Investigational Phase 1 929901-49-5
28
Erlotinib Hydrochloride Phase 1 183319-69-9 176871
29 Protein Kinase Inhibitors Phase 1
30 Immunoglobulins Phase 1
31 Antibodies Phase 1
32 Immunoglobulins, Intravenous Phase 1
33 Antibodies, Monoclonal Phase 1
34 Antiparasitic Agents Phase 1
35 Anti-Bacterial Agents Phase 1
36 Antiprotozoal Agents Phase 1
37 Antineoplastic Agents, Immunological Phase 1

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
2 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
3 A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
4 Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Biliary Tract and Gallbladder Cancer Completed NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
5 A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
6 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
7 Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
8 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2
9 A Multicenter Phase II Study of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Patients With Refractory Advanced Biliary Cancers Withdrawn NCT01859182 Phase 2 selumetinib;Akt inhibitor MK2206
10 A Two-Part Phase I Study of the Addition of Oxaliplatin to Gemcitabine, and Then Erlotinib Plus Oxaliplatin to Gemcitabine as Radiosensitizers for Pancreatic and Biliary Adenocarcinoma Completed NCT00266097 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin;gemcitabine hydrochloride;Oxaliplatin
11 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
12 Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer. Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
13 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
14 A Phase I Study Of Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox -Tricom In Patients With Advanced Or Metastatic Malignancies Expressing CEA Completed NCT00027534 Phase 1
15 Pilot Study of Gemcitabine and IORT/EBRT in Locally Advanced Upper Gastrointestinal Malignancies Completed NCT00544193 Phase 1 gemcitabine hydrochloride
16 A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer Recruiting NCT03257761 Phase 1 Guadecitabine
17 A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma Terminated NCT03267940 Phase 1 PEGPH20;CIS;GEM;Atezolizumab
18 Visceral Lymphatic Mapping Project: A Pilot Study Completed NCT00489515

Search NIH Clinical Center for Gallbladder Adenocarcinoma

Genetic Tests for Gallbladder Adenocarcinoma

Anatomical Context for Gallbladder Adenocarcinoma

MalaCards organs/tissues related to Gallbladder Adenocarcinoma:

40
Liver, Lymph Node, T Cells, Colon, Pancreas, Thyroid, Skin

Publications for Gallbladder Adenocarcinoma

Articles related to Gallbladder Adenocarcinoma:

(show top 50) (show all 484)
# Title Authors PMID Year
1
Concomitant AngioVac thrombectomy and patent foramen ovale closure in a patient with a large right atrial thrombus and recent paradoxical embolic stroke. 61
33599209 2021
2
Reduced MFAP5 expression in stroma of gallbladder adenocarcinoma and its potential diagnostic utility. 61
32895766 2021
3
Immune Microenvironment in Gallbladder Adenocarcinomas. 61
33710123 2021
4
Prognostic Nomograms to Predict Survival of Patients with Resectable Gallbladder Cancer: A Surveillance, Epidemiology, and End Results (SEER)-Based Analysis. 61
33784268 2021
5
Undertreatment of Gallbladder Cancer: A Nationwide Analysis. 61
33566241 2021
6
Factors that Minimize Curative Resection for Gallbladder Adenocarcinoma: an Analysis of Clinical Decision-Making and Survival. 61
33565014 2021
7
Gallbladder Adenocarcinoma: the Impact of Tumor Location and Minimally Invasive Surgery on Survival. 61
33528786 2021
8
A case of gallbladder adenocarcinoma arising in association with intracystic papillary neoplasm (ICPN) with abundant mucin production. 61
32949333 2021
9
Gallbladder carcinoma outcomes in an Australian tertiary referral hospital. 61
33604992 2021
10
Site-specific metastases of gallbladder adenocarcinoma and their prognostic value for survival: a SEER-based study. 61
33485332 2021
11
Long-Lasting Complete Remission of Small-Cell Carcinoma of the Pancreas with Carboplatin and Etoposide Complicated by Gallbladder Adenocarcinoma Diagnosed during Follow-Up. 61
33776730 2021
12
Unusual Case of Gallbladder Adenocarcinoma Metastasis to the Abdominal Wall 11 Years Later: Synchronous Presentation with Two Malignant Colon Tumors, Coincidence or Not? 61
33728090 2021
13
Late Development of Metastatic Ovarian Mucinous Adenocarcinoma From Primary Gallblader Adenocarcinoma and High-grade Dysplasia. 61
32897957 2021
14
Incidence and significance of GATA3 positivity in gallbladder adenocarcinoma. 61
32991930 2020
15
Prognostic impact of lymphovascular invasion in pT1-T3 gallbladder adenocarcinoma. 61
32783204 2020
16
Optimal number of harvested lymph nodes for curatively resected gallbladder adenocarcinoma based on a Bayesian network model. 61
32820544 2020
17
Adeno-squamous and squamous cell carcinoma of the gallbladder: The importance of histology in surgical management. 61
32646581 2020
18
FDG PET/CT of Hepatoid Adenocarcinoma of the Gallbladder. 61
32910054 2020
19
Port-site metastasis of unsuspected gallbladder carcinoma with ossification after laparoscopic cholecystectomy: A case report. 61
33344567 2020
20
Synchronous hepatocellular carcinoma and gallbladder adenocarcinoma with neuroendocrine differentiation: a case report and literature review. 61
33081789 2020
21
Neuroendocrine Carcinomas of the Gallbladder: A Clinicopathologic and Immunohistochemical Analysis of 34 Resected Cases. 61
32739935 2020
22
A comparison of outcomes in patients with intracholecystic papillary neoplasms or conventional adenocarcinomas of the gallbladder. 61
33092965 2020
23
Expression of Insulin-like Growth Factor II mRNA-binding Protein 3 in Gallbladder Carcinoma. 61
32988905 2020
24
Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. 61
32524292 2020
25
Paraneoplastic Dermatomyositis in a Case of Gallbladder Signet Ring Cell Carcinoma. 61
33145135 2020
26
The Spectrum of Gallbladder Histopathology at a Tertiary Hospital in a Developing Country: A Retrospective Study. 61
32923228 2020
27
Prognostic factors and patterns of loco-regional failure in patients with R0 resected gallbladder cancer. 61
31784211 2020
28
Comparative Outcomes of Adenosquamous Carcinoma of the Gallbladder: an Analysis of the National Cancer Database. 61
32705618 2020
29
Haemocholecyst related to gallbladder malignancy. 61
32290760 2020
30
Prognostic factors in patients with gallbladder adenocarcinoma identified using competing-risks analysis: A study of cases in the SEER database. 61
32756116 2020
31
Incidental finding of adenocarcinoma in a gallbladder lumen with no wall involvement. 61
32582429 2020
32
An Important Gallbladder Pathology Mimicking Gallbladder Carcinoma: Xanthogranulomatous Cholecystitis: A Single Tertiary Center Experience. 61
32187090 2020
33
The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy. 61
32109491 2020
34
HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma. 61
31838585 2020
35
Sarcomatoid carcinoma of the gallbladder: a case report. 61
32589472 2020
36
Use of indocyanine green (ICG) augmented near-infrared fluorescence imaging in robotic radical resection of gallbladder adenocarcinomas. 61
31388807 2020
37
Comparison of lymph node evaluation and yield among patients undergoing open and minimally invasive surgery for gallbladder adenocarcinoma. 61
32430521 2020
38
Sinensetin flavone exhibits potent anticancer activity against drug-resistant human gallbladder adenocarcinoma cells by targeting PTEN/PI3K/AKT signalling pathway, induces cellular apoptosis and inhibits cell migration and invasion. 61
32521933 2020
39
Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest. 61
31815765 2020
40
An alpha-fetoprotein-negative hepatoid adenocarcinoma of the gallbladder with squamous differentiation. 61
32140496 2020
41
Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. 61
32012241 2020
42
Differential diagnosis of focal gallbladder lesions: The added value of contrast enhanced ultrasound with liner transducers. 61
31306115 2020
43
Educational Case: Incidental Gallbladder Adenocarcinoma. 61
32206701 2020
44
Prognostic Evaluation for Patients over 45 Years Old with Gallbladder Adenocarcinoma Resection: A SEER-Based Nomogram Analysis. 61
32733948 2020
45
Expression of Formin-like 2 and cortactin in gallbladder adenocarcinoma and their clinical significance. 61
32782685 2020
46
The Efficacy of Adjuvant Chemoradiotherapy in Early-Stage Gallbladder Adenocarcinoma Depends on the Tumor Invasion Depth and Differentiation Level. 61
33392099 2020
47
Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma and Comparison with Gallbladder Adenocarcinoma Using a Propensity Score Matching. 61
32161496 2020
48
Lymph Node Ratio-Based Staging System for Gallbladder Cancer With Fewer Than Six Lymph Nodes Examined. 61
33102214 2020
49
One Hole, Two Tubes, and a Tijuana Pathology Report: A Case Report of Cholecystoduodenal Fistula Mistaken for Gallbladder Cancer. 61
32140360 2020
50
Systematic Selective Sampling of Cholecystectomy Specimens Is Adequate to Detect Incidental Gallbladder Adenocarcinoma. 61
31464710 2019

Variations for Gallbladder Adenocarcinoma

Expression for Gallbladder Adenocarcinoma

Search GEO for disease gene expression data for Gallbladder Adenocarcinoma.

Pathways for Gallbladder Adenocarcinoma

Pathways related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1 12.34 TP53 PIK3CA ERBB2 EGFR
2
Show member pathways
12.31 TP53 PIK3CA ERBB2 EGFR
3
Show member pathways
12.25 TP53 PIK3CA ERBB2 EGFR
4
Show member pathways
12.08 TP53 PIK3CA ERBB2 EGFR
5
Show member pathways
12.06 TP53 PIK3CA ERBB2 EGFR
6 12.05 TP53 PIK3CA ERBB2 EGFR
7 11.82 TP53 PIK3CA ERBB2
8 11.78 PIK3CA ERBB2 EGFR
9
Show member pathways
11.77 PIK3CA ERBB2 EGFR
10
Show member pathways
11.72 TP53 PIK3CA ERBB2 EGFR
11 11.59 TP53 PEG10 MTDH
12 11.53 TP53 PIK3CA ERBB2
13 11.52 TP53 ERBB2 EGFR
14 11.11 TSG101 PIK3CA EGFR
15 11.1 TP53 PIK3CA ERBB2 EGFR
16 11.06 TP53 MTDH EGFR
17 10.92 PIK3CA ERBB2 EGFR
18 10.81 PROM1 ERBB2 EGFR
19 10.74 TP53 PIK3CA MYB ERBB2

GO Terms for Gallbladder Adenocarcinoma

Cellular components related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.02 SLC29A1 PROM1 MTDH ERBB2 EGFR

Biological processes related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.67 ERP29 ERBB2 EPHA7 EGFR
2 positive regulation of kinase activity GO:0033674 9.58 ERBB2 EPHA7 EGFR
3 positive regulation of protein kinase B signaling GO:0051897 9.46 PIK3CA MTDH ERBB2 EGFR
4 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 TP53 EGFR
5 positive regulation of neuron apoptotic process GO:0043525 9.43 TP53 MYB EPHA7
6 negative regulation of ERBB signaling pathway GO:1901185 9.32 ERBB2 EGFR
7 regulation of ERK1 and ERK2 cascade GO:0070372 9.13 ERBB2 EPHA7 EGFR
8 ERBB2 signaling pathway GO:0038128 8.8 PIK3CA ERBB2 EGFR

Molecular functions related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.13 TP53 ERBB2 EGFR
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 ERBB2 EPHA7 EGFR

Sources for Gallbladder Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....